1α,25-Dihydroxyvitamin D3 inhibits transcriptional potential of nuclear factor kappa B in breast cancer cells

Molecular Immunology

Volumn 47, Issue 9, 2010, Pages 1728-1738

  Tse, Anfernee Kai Wing ^a   Zhu, Guo Yuan ^a   Wan, Chi Keung ^a   Shen, Xiao Ling ^a   Yu, Zhi Ling ^a   Fong, Wang Fun ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

Cytokines; Inflammation; NF kappaB; Vitamin D3

Indexed keywords

CALCITRIOL; HISTONE DEACETYLASE 3; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; TRANSCRIPTION FACTOR GAL4; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; HISTONE DEACETYLASE; I KAPPA B; NCOR2 PROTEIN, HUMAN; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; VITAMIN;

ACETYLATION; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DRUG MECHANISM; GENE ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INFLAMMATORY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; ANIMAL; BREAST TUMOR; CELL STRAIN COS1; CERCOPITHECUS; DOWN REGULATION; DRUG EFFECT; FEMALE; GENETICS; HELA CELL; METABOLISM; PATHOLOGY; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION INITIATION; TUMOR CELL LINE; WESTERN BLOTTING;

ACETYLATION; ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CALCITRIOL; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; DOWN-REGULATION; FEMALE; HELA CELLS; HISTONE DEACETYLASES; HUMANS; I-KAPPA B PROTEINS; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; NUCLEAR RECEPTOR CO-REPRESSOR 2; PHOSPHORYLATION; RECEPTORS, CALCITRIOL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA; VITAMINS;

EID: 77952321071     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2010.03.004     Document Type: Article

References (63)

1. Adams L.S., Teegarden D. 1,25-Dihydroxycholecalciferol inhibits apoptosis in C3H10T1/2 murine fibroblast cells through activation of nuclear factor kappaB. J. Nutr. 2004, 134:2948-2952.
2. Aggarwal B.B. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004, 6:203-208.
3. Arriagada G., Paredes R., Olate J., van Wijnen A., Lian J.B., Stein G.S., Stein J.L., Onate S., Montecino M. Phosphorylation at serine 208 of the 1alpha,25-dihydroxy vitamin D3 receptor modulates the interaction with transcriptional coactivators. J. Steroid Biochem. Mol. Biol. 2007, 103:425-429.
4. Auphan N., DiDonato J.A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995, 270:286-290.
5. Baldwin A.S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 1996, 14:649-683.
6. Berry D.M., Clark C.S., Meckling-Gill K.A. 1alpha,25-dihydroxyvitamin D3 stimulates phosphorylation of IkappaBalpha and synergizes with TPA to induce nuclear translocation of NFkappaB during monocytic differentiation of NB4 leukemia cells. Exp. Cell Res. 2002, 272:176-184.
7. Brostjan C., Anrather J., Csizmadia V., Stroka D., Soares M., Bach F.H., Winkler H. Glucocorticoid-mediated repression of NFkappaB activity in endothelial cells does not involve induction of IkappaBalpha synthesis. J. Biol. Chem. 1996, 271:19612-19616.
8. Chaturvedi M.M., Mukhopadhyay A., Aggarwal B.B. Assay for redox-sensitive transcription factor. Methods Enzymol. 2000, 319:585-602.
9. Chen L.F., Mu Y., Greene W.C. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J. 2002, 21:6539-6548.
10. Cohen-Lahav M., Shany S., Tobvin D., Chaimovitz C., Douvdevani A. Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels. Nephrol. Dial. Transplant. 2006, 21:889-897.
11. De Bosscher K., Schmitz M.L., Vanden Berghe W., Plaisance S., Fiers W., Haegeman G. Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:13504-13509.
12. De Martin R., Vanhove B., Cheng Q., Hofer E., Csizmadia V., Winkler H., Bach F.H. Cytokine-inducible expression in endothelial cells of an I kappa B alpha-like gene is regulated by NF kappa B. EMBO J. 1993, 12:2773-2779.
13. Delerive P., De Bosscher K., Vanden Berghe W., Fruchart J.C., Haegeman G., Staels B. DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha. Mol. Endocrinol. 2002, 16:1029-1039.
14. Deroo B.J., Archer T.K. Glucocorticoid receptor activation of the I kappa B alpha promoter within chromatin. Mol. Biol. Cell 2001, 12:3365-3374.
15. Dhawan P., Wieder R., Christakos S. CCAAT enhancer-binding protein alpha is a molecular target of 1,25-dihydroxyvitamin D3 in MCF-7 breast cancer cells. J. Biol. Chem. 2009, 284:3086-3095.
16. Dunlop T.W., Väisänen S., Frank C., Carlberg C. The genes of the coactivator TIF2 and the corepressor SMRT are primary 1alpha,25(OH)2D3 targets. J. Steroid Biochem. Mol. Biol. 2004, 89-90:257-260.
17. Fagerlund R., Kinnunen L., Köhler M., Julkunen I., Melén K. NF-{kappa}B is transported into the nucleus by importin {alpha}3 and importin {alpha}4. J. Biol. Chem. 2005, 280:15942-15951.
18. Froicu M., Weaver V., Wynn T.A., McDowell M.A., Welsh J.E., Cantorna M.T. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol. Endocrinol. 2003, 17:2386-2392.
19. Gorham E.D., Garland F.C., Garland C.F. Sunlight and breast cancer incidence in the USSR. Int. J. Epidemiol. 1990, 19:820-824.
20. Griffin M.D., Dong X., Kumar R. Vitamin D receptor-mediated suppression of RelB in antigen presenting cells: a paradigm for ligand-augmented negative transcriptional regulation. Arch. Biochem. Biophys. 2007, 460:218-226.
21. Harant H., Andrew P.J., Reddy G.S., Foglar E., Lindley I.J. 1alpha,25-dihydroxyvitamin D3 and a variety of its natural metabolites transcriptionally repress nuclear-factor-kappaB-mediated interleukin-8 gene expression. Eur. J. Biochem. 1997, 250:63-71.
22. Hay D.C., Kemp G.D., Dargemont C., Hay R.T. Interaction between hnRNPA1 and IkappaBalpha is required for maximal activation of NF-kappaB-dependent transcription. Mol. Cell. Biol. 2001, 21:3482-3490.
23. Heck S., Bender K., Kullmann M., Göttlicher M., Herrlich P., Cato A.C. I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor. EMBO J. 1996, 16:4698-4707.
24. Hoberg J.E., Popko A.E., Ramsey C.S., Mayo M.W. IkappaB kinase alpha-mediated derepression of SMRT potentiates acetylation of RelA/p65 by p300. Mol. Cell. Biol. 2006, 26:457-471.
25. Hoffmann A., Natoli G., Ghosh G. Transcriptional regulation via the NF-kappaB signaling module. Oncogene 2006, 30:6706-6716.
26. Holtmann H., Winzen R., Holland P., Eickemeier S., Hoffmann E., Wallach D., Malinin N.L., Cooper J.A., Resch K., Kracht M. Induction of interleukin-8 synthesis integrates effects on transcription and mRNA degradation from at least three different cytokine- or stress-activated signal transduction pathways. Mol. Cell. Biol. 1999, 19:6742-6753.
27. Inadera H., Sekiya T., Yoshimura T., Matsushima K. Molecular analysis of the inhibition of monocyte chemoattractant protein-1 gene expression by estrogens and xenoestrogens in MCF-7 cells. Endocrinology 2000, 141:50-59.
28. Issa L.L., Leong G.M., Barry J.B., Sutherland R.L., Eisman J.A. Glucocorticoid receptor-interacting protein-1 and receptor-associated coactivator-3 differentially interact with the vitamin D receptor (VDR) and regulate VDR-retinoid X receptor transcriptional cross-talk. Endocrinology 2001, 142:1606-1615.
29. Jana M., Jana A., Liu X., Ghosh S., Pahan K. Involvement of phosphatidylinositol 3-kinase-mediated up-regulation of I kappa B alpha in anti-inflammatory effect of gemfibrozil in microglia. J. Immunol. 2007, 179:4142-4152.
30. Jiang X., Takahashi N., Matsui N., Tetsuka T., Okamoto T. The NF-kappa B activation in lymphotoxin beta receptor signaling depends on the phosphorylation of p65 at serine 536. J. Biol. Chem. 2003, 278:919-926.
31. Jimenez-Lara A.M., Aranda A. The vitamin D receptor binds in a transcriptionally inactive form and without a defined polarity on a retinoic acid response element. FASEB J. 1999, 13:1073-1081.
32. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 2000, 18:621-663.
33. Koschmieder S., Halmos B., Levantini E., Tenen D.G. Dysregulation of the C/EBPalpha differentiation pathway in human cancer. J. Clin. Oncol. 2009, 27:619-628.
34. Liberman U.A. Vitamin D-resistant diseases. J. Bone Miner. Res. 2007, 22:V105-107.
35. Malloy P.J., Xu R., Peng L., Clark P.A., Feldman D. A novel mutation in helix 12 of the vitamin D receptor impairs coactivator interaction and causes hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia. Mol. Endocrinol. 2002, 16:2538-2546.
36. Mercurio F., Zhu H., Murray B.W., Shevchenko A., Bennett B.L., Li J., Young D.B., Barbosa M., Mann M., Manning A., Rao A. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 1997, 278:860-866.
37. Nakshatri H., Bhat-Nakshatri P., Martin D.A., Goulet R.J., Sledge G.W. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol. Cell. Biol. 1997, 17:3629-3639.
38. Ordonez-Moran P., Larriba M.J., Pendas-Franco N., Aguilera O., Gonzalez-Sancho J.M., Munoz A. Vitamin D and cancer: an update of in vitro and in vivo data. Front. Biosci. 2005, 10:2723-2749.
39. Pascual G., Glass C.K. Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol. Metab. 2006, 17:321-327.
40. Paz-Priel I., Ghosal A.K., Kowalski J., Friedman A.D. C/EBPalpha or C/EBPalpha oncoproteins regulate the intrinsic and extrinsic apoptotic pathways by direct interaction with NF-kappaB p50 bound to the bcl-2 and FLIP gene promoters. Leukemia 2009, 23:365-374.
41. Pendás-Franco N., González-Sancho J.M., Suárez Y., Aguilera O., Steinmeyer A., Gamallo C., Berciano M.T., Lafarga M., Muñoz A. Vitamin D regulates the phenotype of human breast cancer cells. Differentiation 2007, 75:193-207.
42. Ping D., Jones P.L., Boss J.M. TNF regulates the in vivo occupancy of both distal and proximal regulatory regions of the MCP-1/JE gene. Immunity 1996, 4:455-469.
43. Privalsky M.L. The role of corepressors in transcriptional regulation by nuclear hormone receptors. Annu. Rev. Physiol. 2004, 66:315-360.
44. Riis J.L., Johansen C., Gesser B., Møller K., Larsen C.G., Kragballe K., Iversen L. 1alpha,25(OH)(2)D(3) regulates NF-kappaB DNA binding activity in cultured normal human keratinocytes through an increase in IkappaBalpha expression. Arch. Dermatol. Res. 2004, 296:195-202.
45. Sakurai H., Chiba H., Miyoshi H., Sugita T., Toriumi W. IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J. Biol. Chem. 1999, 274:30353-30356.
46. Sánchez-Martínez R., Zambrano A., Castillo A.I., Aranda A. Vitamin D-dependent recruitment of corepressors to vitamin D/retinoid X receptor heterodimers. Mol. Cell. Biol. 2008, 28:3817-3829.
47. Scheinman R.I., Cogswell P.C., Lofquist A.K., Baldwin A.S. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995, 270:283-286.
48. Sun J., Kong J., Duan Y., Szeto F.L., Liao A., Madara J.L., Li Y.C. Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor. Am. J. Physiol. Endocrinol. Metab. 2006, 291:E315-E322.
49. Sun J., Mustafi R., Cerda S., Chumsangsri A., Xia Y.R., Li Y.C., Bissonnette M. Lithocholic acid down-regulation of NF-kappaB activity through vitamin D receptor in colonic cancer cells. J. Steroid Biochem. Mol. Biol. 2008, 111:37-40.
50. Tan X., Wen X., Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J. Am. Soc. Nephrol. 2008, 19:1741-1752.
51. Tsai E.Y., Jain J., Pesavento P.A., Rao A., Goldfeld A.E. Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. Mol. Cell. Biol. 1996, 16:459-467.
52. Tse A.K., Wan C.K., Shen X.L., Zhu G.Y., Cheung H.Y., Yang M., Fong W.F. 1,25-Dihydroxyvitamin D3 induces biphasic NF-kappaB responses during HL-60 leukemia cells differentiation through protein induction and PI3K/Akt-dependent phosphorylation/degradation of IkappaB. Exp. Cell Res. 2007, 313:1722-1734.
53. Ueda A., Ishigatsubo Y., Okubo T., Yoshimura T. Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of two NF-kappaB sites and NF-kappaB/Rel subunit specificity. J. Biol. Chem. 1997, 272:31092-31099.
54. Valdivielso J.M., Fernandez E. Vitamin D receptor polymorphisms and diseases. Clin. Chim. Acta 2006, 371:1-12.
55. Van Etten E., Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J. Steroid Biochem. Mol. Biol. 2005, 97:93-101.
56. Van Laere S.J., Van der Auwera I., Van den Eynden G.G., Elst H.J., Weyler J., Harris A.L., van Dam P., Van Marck E.A., Vermeulen P.B., Dirix L.Y. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin. Cancer Res. 2006, 12:3249-3256.
57. Vasanwala F.H., Kusam S., Toney L.M., Dent A.L. Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene. J. Immunol. 2002, 169:1922-1929.
58. Wang T.T., Tavera-Mendoza L.E., Laperriere D., Libby E., MacLeod N.B., Nagai Y., Bourdeau V., Konstorum A., Lallemant B., Zhang R., Mader S., White J.H. Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol. Endocrinol. 2005, 19:2685-2695.
59. Wittke A., Chang A., Froicu M., Harandi O.F., Weaver V., August A., Paulson R.F., Cantorna M.T. Vitamin D receptor expression by the lung micro-environment is required for maximal induction of lung inflammation. Arch. Biochem. Biophys. 2007, 460:306-313.
60. Wu J.T., Kral J.G. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J. Surg. Res. 2005, 123:158-169.
61. Zhang Z., Yuan W., Sun L., Szeto F.L., Wong K.E., Li X., Kong J., Li Y.C. 1,25-Dihydroxyvitamin D3 targeting of NF-kappaB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int. 2007, 72:193-201.
62. Zhong H., Voll R.E., Ghosh S. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol. Cell 1998, 1:661-671.
63. Zou A., Elgort M.G., Allegretto E.A. Retinoid X receptor (RXR) ligands activate the human 25-hydroxyvitamin D3-24-hydroxylase promoter via RXR heterodimer binding to two vitamin D-responsive elements and elicit additive effects with 1,25-dihydroxyvitamin D3. J Biol. Chem. 1997, 272:19027-19034.